Vol 7 Issue 7

Clinical trial design, supply chain and operations

Jul 2021

Editorial

CRISPR gene editing for sickle cell disease: one disease, differentiated approaches

Lisa A Michaels, MD,

Bruce E Eaton, PhD

5 August 2021

Editorial

Innovator Insight

Preparing for pivotal: solving challenges in scale for cell and gene therapy clinical trials

Subbu Viswanathan,

Richard Gaeto,

Erin Goodhue Meyer,

Chris Greenberg,

Jim Wise

5 August 2021

Innovator Insight

Interview

Strengthening the clinical supply chain for individualized therapies

James Andrew Case

5 August 2021

Interview

Driving clinical progress of gene therapy in cystic fibrosis

Uta Griesenbach

28 July 2021

Interview

Challenges in the gene therapy of bone marrow failure syndromes

Juan Bueren

16 July 2021

Interview

Learning lessons from the long, troubled history of stem cell therapy for future clinical success

John EJ Rasko

15 July 2021

Interview

Addressing issues in clinical development of AAV-driven gene therapy

Sabah Sallah

14 July 2021

Interview

Global commercial strategies

Interview

Evolution and innovation in autologous cell therapy supply chain

Sadia L’Baouch

18 August 2021

Interview

On Demand Webinar

Importance of high-quality starting material for success in advanced therapy

Bob Amareld,

Nathan Frank, MS,

Jason C Lin,

Richard McFarland,

John Paul Tomtishen III

12 August 2021

On Demand Webinar

Business Insights July 2021

Expert Insight

Solving the problem of financing one-time treatments with evidence uncertainty: which types of outcomes-based payment models could work best for novel CAR-T therapies in multiple myeloma? A systematic review of the published literature

Cassidy-Candice Dietrich,

Clare Hague,

Stefan Boes

8 July 2021

Expert Insight

Commentary

Critical need for establishing value that justifies the current rising costs of cell and gene therapy

Richard T Maziarz, MD

9 July 2021

Commentary

Innovator Insight

When using a closed and automated manufacturing platform, is there an option to maintain flexibility?

Kaman Kim,

Carlos Yuraszeck,

Joseph O’Connor

12 August 2021

Innovator Insight

Delivering an end-to-end industrialization roadmap for autologous cell therapy

Matt Hewitt, PhD, Senior Director, Scientific Services, Cell and Gene Therapy, Charles River Laboratories

Joe Garrity, Head of Autologous Cell Therapy Commercial Development, CGT, Lonza

Walter Bagni, Cell & Gene Technologies & Labelling CoE Lead, Lonza

6 July 2021

Webinar

Watch now

Assuring manufacturing and data integrity for cell and gene therapy regulatory compliance

Jelena Jurlin, Head of Compliance, Lonza

Dr. Dmitry Fridman, Global Product Manager, Miltenyi Biotec B.V. & Co. KG

14 July 2021

Webinar

Watch now

Expression systems for viral vector production: advantages of the Sf9 Baculovirus system and simple solutions to address its specific analytical challenges

Yi Fang Lee, R&D Scientist, Thermo Fisher Scientific

Srinath Kashi Ranganath, Staff Scientist – Field Applications, Thermo Fisher Scientific

22 July 2021

Webinar

Watch now

CELL & GENE THERAPY INSIGHTS

Jul 2021. Vol 7 Issue 7

FEATURING

Spotlight

Clinical trial design, supply chain and operations

Editorial

CRISPR gene editing for sickle cell disease: one disease, differentiated approaches

Innovator Insight

Preparing for pivotal: solving challenges in scale for cell and gene therapy clinical trials

Interview

Strengthening the clinical supply chain for individualized therapies

Driving clinical progress of gene therapy in cystic fibrosis

Challenges in the gene therapy of bone marrow failure syndromes

Learning lessons from the long, troubled history of stem cell therapy for future clinical success

Addressing issues in clinical development of AAV-driven gene therapy

Supply Chain FOCUS

Global commercial strategies

Interview

Evolution and innovation in autologous cell therapy supply chain

On Demand Webinar

Importance of high-quality starting material for success in advanced therapy

Report

Business Insights July 2021

Expert Insight

Solving the problem of financing one-time treatments with evidence uncertainty: which types of outcomes-based payment models could work best for novel CAR-T therapies in multiple myeloma? A systematic review of the published literature

Commentary

Critical need for establishing value that justifies the current rising costs of cell and gene therapy

Other articles

Innovator Insight

When using a closed and automated manufacturing platform, is there an option to maintain flexibility?

Webinars

Delivering an end-to-end industrialization roadmap for autologous cell therapy

Assuring manufacturing and data integrity for cell and gene therapy regulatory compliance

Expression systems for viral vector production: advantages of the Sf9 Baculovirus system and simple solutions to address its specific analytical challenges